Epidemiology and Management of Rare Cancers

Rare cancers collectively account for approximately 20–25% of all malignancies yet each individual entity occurs at a rate below 6 per 100 000 per year. This low incidence and vast histological diversity pose obstacles to accurate measurement of disease burden, leading to gaps in epidemiological surveillance and inconsistent registry practices across regions. Global registries and harmonised classification systems have begun to shed light on geographical variations in incidence and survival, revealing disparities in diagnosis and access to specialised services. Management of rare cancers demands a multidisciplinary approach encompassing centralised referral to expert centres, comprehensive genomic profiling, and adaptive clinical trial designs that accommodate small patient populations. Advances in sequencing and target identification have yielded precision therapies for subsets of rare tumours, while real-world evidence from hospital and network registries informs prognostic factors and quality-of-care indicators. Multinational collaborations, unified data platforms and innovative trial methodologies aim to accelerate the translation of novel interventions into practice, reduce time to diagnosis, and improve long-term outcomes. Continued emphasis on standardising epidemiological methods, expanding access to molecular diagnostics and developing patient-centric networks is essential to address the unique challenges presented by rare cancers and to ensure equitable care worldwide.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Epidemiology and Management of Rare Cancers publication trend

The graph below shows the total number of articles in epidemiology and management of rare cancers across all publications each year (not limited to Nature Index journals).

Technical terms

Incidence: The number of new cases of a disease per population unit within a specified time period.

Net survival: The probability of surviving a specific disease after adjusting for mortality from other causes.

Tumour registry: A systematic collection of detailed information on patients diagnosed with specific tumour types.

Genomic profiling: Assessment of tumour DNA to identify mutations and alterations that may guide targeted therapy.

Targetable genomic alteration: A genetic change in a tumour for which specific drug interventions exist or are in development.

Progression-free survival: The duration during and after treatment in which a patient’s disease does not worsen.

References

1. Incidence and survival of rare cancers in the US and Europe. Cancer Medicine (2020).
2. Comprehensive Genomic Profiling of Rare Tumors: Routes to Targeted Therapies. Frontiers in Oncology (2020).
3. The observational clinical registry (cohort design) of the European Reference Network on Rare Adult Solid Cancers: The protocol for the rare head and neck cancers. PLOS ONE (2023).
4. Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative. European Journal of Cancer (2014).